All these mutations can act by altering many signaling pathways, such as NFkB, MAPK, and PI3K/AKT/mTOR, which in turn mediate the overexpression of EGFR [13]; this point in cSCC is commonly associated with a more aggressive phenotype and a poor prognosis for the patient but can, however, be targeted with specific drugs to inhibit cSCC progression [8]. The gene discussed is MTOR; the disease is skin squamous cell carcinoma.